- Home
- DRMA
as 12-18-2024 2:35pm EST
Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 2.2M | IPO Year: | 2021 |
| Target Price: | $6.00 | AVG Volume (30 days): | 588.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -15.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.03 - $13.35 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Dermata Therapeutics Inc. News
DRMA Breaking Stock News: Dive into DRMA Ticker-Specific Updates for Smart Investing
ACCESSWIRE
2 days ago
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)
ACCESSWIRE
8 days ago
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne
ACCESSWIRE
15 days ago
Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
GlobeNewswire
a month ago
Life Sciences Investor Forum: Presentations Now Available for Online Viewing
ACCESSWIRE
a month ago
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
GlobeNewswire
a month ago
Life Sciences Investor Forum Agenda Announced for November 14th
GlobeNewswire
a month ago
Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024
ACCESSWIRE
2 months ago
Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024
Compare DRMA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DRMA Dermata Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.